Clinical trial • Phase I • Oncology
GSK5733584 for Injection for Ovarian cancer
Phase I trial of GSK5733584 for Injection for Ovarian cancer. 232 participants.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Ovarian cancer
- Trial Stage
- Phase I
Key dates
- Initial CTIS Submission Date
- 03-07-2024
- First CTIS Authorization Date
- 22-10-2024
Trial design
Phase I trial across 27 sites in Netherlands, Sweden, Italy and others.
- Target Sample Size
- 232
Recruitment
- Planned Sample Size
- 232
- Recruitment Window Months
- 34
Geography
- Total Number Of Sites
- 27
- Total Number Of Participants
- 143
Netherlands
- Earliest CTIS Part Ii Submission Date
- 14-10-2024
- Latest Decision Or Authorization Date
- 23-10-2024
- Processing Time Days
- 9
- Number Of Sites
- 1
- Number Of Participants
- 15
Sites
- Site Name
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Department Name
- Medical Oncology
- Contact Person Name
- Marloes van Dongen
- Contact Person Email
- fase1@nki.nl
Sweden
- Earliest CTIS Part Ii Submission Date
- 22-07-2024
- Latest Decision Or Authorization Date
- 24-10-2024
- Processing Time Days
- 94
- Number Of Sites
- 2
- Number Of Participants
- 12
Sites
- Site Name
- Uppsala University Hospital
- Department Name
- KFUE - Kliniska forsknings- och utvecklingsenheten, Blod- och Tumörsjukdomar
- Contact Person Name
- Anthoula Koliadi
- Contact Person Email
- kliniskaprovningar@akademiska.se
- Site Name
- Karolinska University Hospital
- Department Name
- Centrum för Kliniska Cancerstudier Tema Cancer
- Contact Person Name
- Lisa Liu Burström
- Contact Person Email
- firstname.lastname@regionstockholm.se
Italy
- Earliest CTIS Part Ii Submission Date
- 04-10-2024
- Latest Decision Or Authorization Date
- 22-10-2024
- Processing Time Days
- 18
- Number Of Sites
- 5
- Number Of Participants
- 33
Sites
- Site Name
- IRCCS Istituto Nazionale Tumori Fondazione Pascale
- Department Name
- S.C. Sperimentazioni Cliniche
- Contact Person Name
- Adriano Gravina
- Contact Person Email
- a.gravina@istitutotumori.na.it
- Site Name
- Humanitas Mirasole S.p.A.
- Department Name
- Phase I Clinical Trial Unit
- Contact Person Name
- Domenica Lorusso
- Contact Person Email
- domenica.lorusso@hunimed.eu
- Site Name
- Istituto Europeo Di Oncologia S.r.l.
- Department Name
- Divisione Sviluppo di Nuovi Farmaci per Terapie Innovative
- Contact Person Name
- Giuseppe Curigliano
- Contact Person Email
- giuseppe.curigliano@ieo.it
- Site Name
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- Department Name
- Unità di Fase 1: Unità di Farmacologia Clinica
- Contact Person Name
- Vanda Salutari
- Contact Person Email
- vanda.salutari@policlinicogemelli.it
- Site Name
- Centro Di Riferimento Oncologico Di Aviano
- Department Name
- S.O.C. Oncologia Medica e Prevenzione oncologica (OMP)
- Contact Person Name
- Michele Bartoletti
- Contact Person Email
- michele.bartoletti@cro.it
Belgium
- Earliest CTIS Part Ii Submission Date
- 01-10-2024
- Latest Decision Or Authorization Date
- 25-10-2024
- Processing Time Days
- 24
- Number Of Sites
- 1
- Number Of Participants
- 11
Sites
- Site Name
- UZ Leuven
- Department Name
- Gynaecological oncology
- Contact Person Name
- Toon Van Gorp
- Contact Person Email
- toon.vangorp@uzleuven.be
France
- Earliest CTIS Part Ii Submission Date
- 27-09-2024
- Latest Decision Or Authorization Date
- 24-10-2024
- Processing Time Days
- 27
- Number Of Sites
- 3
- Number Of Participants
- 26
Sites
- Site Name
- Institut Gustave Roussy
- Department Name
- Medical Oncology
- Contact Person Name
- Alexandra LEARY
- Contact Person Email
- alexandra.leary@gustaveroussy.fr
- Site Name
- Institut De Cancerologie De L Ouest
- Department Name
- Medical oncology
- Contact Person Name
- Jean-Sebastien FRENEL
- Contact Person Email
- jean-sebastien.frenel@ico.unicancer.fr
- Site Name
- Centre Leon Berard
- Department Name
- Medical Oncology
- Contact Person Name
- Isabelle RAY-COQUARD
- Contact Person Email
- isabelle.ray-coquard@lyon.unicancer.fr
Finland
- Earliest CTIS Part Ii Submission Date
- 23-09-2024
- Latest Decision Or Authorization Date
- 23-10-2024
- Processing Time Days
- 30
- Number Of Sites
- 3
- Number Of Participants
- 18
Sites
- Site Name
- Tampere University Hospital
- Department Name
- FONK (oncological clinical trial unit)
- Contact Person Name
- Synnöve Staff
- Contact Person Email
- etunimi.sukunimi@pirha.fi
- Site Name
- HUS-Yhtymae
- Department Name
- HUS Comprehensive Cancer center
- Contact Person Name
- Katriina Jalkanen
- Contact Person Email
- etunimi.sukunimi@hus.fi
- Site Name
- Docrates Oy
- Department Name
- Docrates Cancer Center
- Contact Person Name
- Johanna Mäenpää
- Contact Person Email
- etunimi.sukunimi@docrates.com
Germany
- Earliest CTIS Part Ii Submission Date
- 06-02-2026
- Latest Decision Or Authorization Date
- 23-02-2026
- Processing Time Days
- 17
- Number Of Sites
- 4
- Number Of Participants
- 8
Sites
- Site Name
- Charite Universitaetsmedizin Berlin KöR
- Department Name
- Klinik für Gynäkologie mit Zentrum f onkologische Chirurgie (CVK) u Klinik f Gynäkologie (CBF)
- Contact Person Name
- Elena Braicu
- Contact Person Email
- elena.braicu@charite.de
- Site Name
- Universitaetsklinikum Ulm AöR
- Department Name
- Tumorzentrum Alb-Allgäu-Bodensee Integratives Tumorzentrum
- Contact Person Name
- Sabine Heublein
- Contact Person Email
- sabine.heublein@uniklinik-ulm.de
- Site Name
- Technische Universitaet Dresden
- Department Name
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe
- Contact Person Name
- Pauline Wimberger
- Contact Person Email
- pauline.wimberger@uniklinikum-dresden.de
- Site Name
- Universitaetsklinikum Heidelberg AöR
- Department Name
- Klinik für Frauenheilkunde und Geburtshilfe
- Contact Person Name
- Katharina Smetanay
- Contact Person Email
- katharina.smetanay@med.uni-heidelberg.de
Spain
- Earliest CTIS Part Ii Submission Date
- 02-10-2024
- Latest Decision Or Authorization Date
- 22-10-2024
- Processing Time Days
- 20
- Number Of Sites
- 8
- Number Of Participants
- 20
Sites
- Site Name
- Institut Catala D'oncologia
- Department Name
- Oncología Médica
- Contact Person Name
- Pilar Barretina Ginesta
- Contact Person Email
- mpbarretina@iconcologia.net
- Site Name
- Clinica Universidad De Navarra
- Department Name
- Oncología Médica
- Contact Person Name
- Antonio González Martín
- Contact Person Email
- ensayoscun@unav.es
- Site Name
- Hospital Universitario Reina Sofia
- Department Name
- Oncología Médica
- Contact Person Name
- María Jesús Rubio Pérez
- Contact Person Email
- mjesusrubio63@gmail.com
- Site Name
- Hospital Universitario La Paz
- Department Name
- Oncología Médica
- Contact Person Name
- Andrés Redondo Sánchez
- Contact Person Email
- andres.redondo@salud.madrid.org
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Oncología Médica
- Contact Person Name
- Lorena Fariñas Madrid
- Contact Person Email
- lfarinas@vhio.net
- Site Name
- Hospital Universitario Ramon Y Cajal
- Department Name
- Oncología Médica
- Contact Person Name
- Eva María Guerra Alía
- Contact Person Email
- evamaria.guerra@salud.madrid.org
- Site Name
- Hospital Universitario Quironsalud Madrid
- Department Name
- Next Oncology – Oncología médica
- Contact Person Name
- Valentina Boni
- Contact Person Email
- vboni@nextoncology.eu
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Oncología Médica
- Contact Person Name
- Victor Moreno García
- Contact Person Email
- victor.moreno@startmadrid.com
Sponsor
Primary sponsor
- Full Name
- Glaxosmithkline Research & Development Limited
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United Kingdom
Investigational products
- Investigational Product Name
- GSK5733584 for Injection
- Routes Of Administration
- for Injection
- Route
- for Injection
Related trials
Other published trials that may interest you.